Concord Drugs Limited has issued a formal disclosure to the Bombay Stock Exchange regarding the distribution of its Annual Report for the financial year ended March 31, 2026. The company is sending letters to members who have not registered their email addresses with the registrar or depository participants.

Regulatory Compliance and Access

Pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Drugs is required to provide a web link and exact path to access the complete annual report for shareholders without registered email IDs. The document is available on the company’s website under the Investor Relations section.

The management urges shareholders to update their email addresses with their respective Depository Participants. This step is essential for receiving future communications electronically in accordance with the Companies Act, 2013, and SEBI LODR regulations.

Upcoming Shareholder Meeting

The company has scheduled its 31st Annual General Meeting for Wednesday, September 30, 2026. The meeting will be held at 9:30 am through Video Conferencing or Other Audio Visual Means, as permitted by the Ministry of Corporate Affairs and SEBI circulars.

Shareholders whose email addresses are registered will receive the AGM notice and the annual report electronically. Those with unregistered emails are directed to use the provided web link to review the documents prior to the meeting.

Concord Drugs Limited reported a significant turnaround in profitability for the first quarter of FY27, with standalone net profit surging 901% year-on-year to ₹1.11 crore. The Hyderabad-based pharmaceutical company posted consolidated net profit of ₹1.11 crore for the quarter ended June 30, 2026, compared to ₹0.12 crore in the same period last year. This sharp improvement demonstrates stronger earnings generation even as the company navigated a 33% dilution in its equity share base due to a recent preferential issue.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 10, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, Pundarikashyam & Associates, issued a limited review report on the financial statements. The results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013.

Financial Performance Highlights

Standalone revenue from operations stood at ₹20.89 lakh for the quarter, up from ₹13.38 lakh in Q1FY26. For the full fiscal year ended March 31, 2026, total revenue reached ₹75.85 lakh. Consolidated net sales were slightly higher at ₹20.94 lakh for the current quarter. The company’s paid-up capital remained at ₹13.18 crore, reflecting the inclusion of shares allotted through the preferential issue.

Consolidated figures mirrored this trend, with profit before tax rising to ₹1.54 lakh from ₹0.16 lakh in the prior year period. Basic earnings per share (EPS) improved to ₹0.84 from ₹0.11 on a standalone basis, and ₹0.85 from ₹0.12 on a consolidated basis.

What the Numbers Show

The most notable aspect of this quarter is the resilience of earnings per share despite significant equity dilution. The company allotted 31,75,000 equity shares at ₹36.50 per share through a preferential issue during the quarter ended March 31, 2026, increasing its weighted average number of equity shares outstanding by over 33%. Typically, such dilution pressures EPS metrics. However, Concord Drugs managed to grow its net profit at a rate that outpaced the expansion of its share base. This indicates that the operational efficiency and revenue growth were sufficient to absorb the dilution impact, delivering higher returns per share to existing investors.

The subsidiary, Proton Remedies Private Limited, contributed ₹0.37 lakh in revenue and ₹0.002 lakh in net profit after tax for the quarter. The consolidated results include the financials of this entity, which were reviewed by their respective independent auditors. The company’s other equity increased to ₹36.45 lakh from ₹35.34 lakh in the previous quarter, reflecting retained earnings accumulation.